ARTHEx Biotech Welcomes Glenn P. Sblendorio as New Chairman to Drive Growth
In a strategic move aimed at strengthening its leadership, ARTHEx Biotech has announced the appointment of Glenn P. Sblendorio, M.B.A., as the new Chairman of its Board of Directors. This decision aligns with the company's mission to advance RNA-based therapeutics for neuromuscular disorders, particularly emphasizing the development of its lead product, ATX-01, which is currently undergoing clinical evaluation.
Glenn Sblendorio brings over three decades of distinguished experience in the biotechnology sector to ARTHEx. His previous roles include positions as the Chief Executive Officer of IVERIC bio, Inc., recently acquired by Astellas Pharma, Inc., and as President and Chief Financial Officer of The Medicines Company, which was also acquired—this time by Novartis. His expertise spans corporate strategy, finance, business development, and capital markets, making him an invaluable asset during this pivotal time for ARTHEx.
Frédéric Legros, CEO of ARTHEx Biotech, expressed enthusiasm regarding Sblendorio's appointment. He stated, "We are thrilled to welcome Glenn as Chairman of our Board during this exciting period for ARTHEx. As we continue our critical work on advancing ATX-01 through its clinical trials and look to expand our proprietary BOOST-ON™ platform, Glenn's insightful leadership will be instrumental." The BOOST-ON™ platform is engineered to effectively deliver RNA therapeutics to multiple target areas, including skeletal muscles, heart, and brain, potentially revolutionizing treatment methodologies for a range of neuromuscular diseases.
Sblendorio's extensive background is further evidenced by his prior experience as Executive Vice President and Chief Financial Officer at Eyetech Pharmaceuticals, Inc. He also played a controlling role at MPM Capital Advisors. Currently, he serves on the boards of other noteworthy biotech firms, including Mineralys Therapeutics, Inc. and Amicus Therapeutics, Inc., showcasing his extensive network and influence within the biotech community.
Commenting on his new role, Sblendorio shared, "I am excited to join ARTHEx as Chairman at such an important stage in the company's evolution. The company's innovative RNA therapeutics platform has the potential to address the underlying biology behind serious diseases, and I’m eager to contribute to its strategic vision. I look forward to collaborating with Fred, the Board and the entire team as we work to fulfill our mission of bringing transformative therapeutic solutions to patients in need."
The focus of ARTHEx's BOOST-ON™ platform lies in effectively targeting RNA therapies to diseased tissues. This unique approach enhances tissue delivery for significant conditions like myotonic dystrophy type 1 (DM1). The commitment to leveraging advanced RNA technology places ARTHEx at the forefront of biotechnology innovation. Earlier studies focused on the BOOST-ON™ platform have indicated functional improvements in muscle tissue amidst preclinical trials, giving rise to optimism regarding its capacity to treat both muscular and central nervous system disorders.
Located in Valencia, Spain, ARTHEx Biotech stands as a beacon of innovation in the realm of genetic medicine, aiming to revolutionize the treatment landscape for rare neuromuscular disorders. By appointing Sblendorio as Chairman, ARTHEx underscores its commitment to scientific advancement and corporate growth, hoping to capitalize on emerging opportunities for healing and rehabilitation in the biotechnology space. The company anticipates that Sblendorio's leadership will attract further investment and support the ongoing development of therapies that address critical unmet medical needs. As ARTHEx looks to the future, there is a palpable excitement around the possibilities that lie ahead, fueled by innovative science and strategic management.
Glenn Sblendorio brings over three decades of distinguished experience in the biotechnology sector to ARTHEx. His previous roles include positions as the Chief Executive Officer of IVERIC bio, Inc., recently acquired by Astellas Pharma, Inc., and as President and Chief Financial Officer of The Medicines Company, which was also acquired—this time by Novartis. His expertise spans corporate strategy, finance, business development, and capital markets, making him an invaluable asset during this pivotal time for ARTHEx.
Frédéric Legros, CEO of ARTHEx Biotech, expressed enthusiasm regarding Sblendorio's appointment. He stated, "We are thrilled to welcome Glenn as Chairman of our Board during this exciting period for ARTHEx. As we continue our critical work on advancing ATX-01 through its clinical trials and look to expand our proprietary BOOST-ON™ platform, Glenn's insightful leadership will be instrumental." The BOOST-ON™ platform is engineered to effectively deliver RNA therapeutics to multiple target areas, including skeletal muscles, heart, and brain, potentially revolutionizing treatment methodologies for a range of neuromuscular diseases.
Sblendorio's extensive background is further evidenced by his prior experience as Executive Vice President and Chief Financial Officer at Eyetech Pharmaceuticals, Inc. He also played a controlling role at MPM Capital Advisors. Currently, he serves on the boards of other noteworthy biotech firms, including Mineralys Therapeutics, Inc. and Amicus Therapeutics, Inc., showcasing his extensive network and influence within the biotech community.
Commenting on his new role, Sblendorio shared, "I am excited to join ARTHEx as Chairman at such an important stage in the company's evolution. The company's innovative RNA therapeutics platform has the potential to address the underlying biology behind serious diseases, and I’m eager to contribute to its strategic vision. I look forward to collaborating with Fred, the Board and the entire team as we work to fulfill our mission of bringing transformative therapeutic solutions to patients in need."
The focus of ARTHEx's BOOST-ON™ platform lies in effectively targeting RNA therapies to diseased tissues. This unique approach enhances tissue delivery for significant conditions like myotonic dystrophy type 1 (DM1). The commitment to leveraging advanced RNA technology places ARTHEx at the forefront of biotechnology innovation. Earlier studies focused on the BOOST-ON™ platform have indicated functional improvements in muscle tissue amidst preclinical trials, giving rise to optimism regarding its capacity to treat both muscular and central nervous system disorders.
Located in Valencia, Spain, ARTHEx Biotech stands as a beacon of innovation in the realm of genetic medicine, aiming to revolutionize the treatment landscape for rare neuromuscular disorders. By appointing Sblendorio as Chairman, ARTHEx underscores its commitment to scientific advancement and corporate growth, hoping to capitalize on emerging opportunities for healing and rehabilitation in the biotechnology space. The company anticipates that Sblendorio's leadership will attract further investment and support the ongoing development of therapies that address critical unmet medical needs. As ARTHEx looks to the future, there is a palpable excitement around the possibilities that lie ahead, fueled by innovative science and strategic management.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.